Pfizer Inc.

NYSE:PFE  
39.58
+0.38 (+0.98%)
4:03:58 PM EDT: $39.50 -0.08 (-0.19%)
Products, Expansion, Regulatory

Pfizer And Biontech Propose Expansion Of Pivotal Covid-19 Vaccine Trial

Published: 09/12/2020 15:06 GMT
Pfizer Inc. (PFE) - Pfizer and Biontech Propose Expansion of Pivotal Covid-19 Vaccine Trial.
Pfizer - Submitted Amended Protocol to U.S. FDA to Expand Enrollment of Phase 3 Pivotal Covid-19 Vaccine Trial to Up to About 44,000 Participants.
Pfizer - Enrollment in Trial Has Been Proceeding As Planned and Company Expects to Reach Its Initial Target of Up to 30,000 Participants Next Week.
Pfizer - Proposed Expansion Would Allow the Companies to Further Increase Trial Population Diversity.
Pfizer - Companies Continue to Expect That a Conclusive Readout on Efficacy is Likely by the End of October.